Investors

Financials & Filings

Filing date Form Description Filing Group View
SC 13G/A

An amendment to the SC 13G filing

Other
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC 13D/A

An amendment to a SC 13D filing

Other
8-K/A

Amendment to a previously filed 8-K

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K/A

Amendment to a previously filed 8-K

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

Current Reports
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
RW

Withdrawal of registration statement filed under the Securities Act

Other
SC 13D/A

An amendment to a SC 13D filing

Other
3/A

An amendment to a 3 filing. Non-EDGAR filing

3,4,5

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.